{"filing":{"accession_number":"0001437749-26-023538","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"crvo20260714_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926023538/crvo20260714_8k.htm"},"events":[{"id":17871,"run_id":16031,"accession_number":"0001437749-26-023538","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic analyses, and Phase 2 study findings for an 80 mg BID dose. These data support the company's planned Phase 3 trial design and dose selection, representing a material clinical development milestone for the company's lead drug candidate.","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16500,"accession_number":"0001437749-26-023538","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026. The disclosure details Phase 2b trial results, PK-PD analyses, and a Phase 2 study of an alternative dose, supporting the company's planned Phase 3 trial design and dose selection. This is a material clinical development milestone for a clinical-stage biotech company's lead drug candidate, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types—it is a material operational/clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:22:43.148257+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16501,"accession_number":"0001437749-26-023538","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed disclosed new clinical trial data and analyses for neflamapimod presented at AAIC 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic relationships, and Phase 2 study findings for an 80 mg BID dose. The disclosure centers on clinical development progress, dosing strategy refinement, and biomarker/imaging data supporting advancement toward Phase 3 trials—a material operational and strategic milestone for a clinical-stage biopharmaceutical company, though not fitting the specific categories of earnings, M\u0026A, litigation, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:22:43.148257+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16500,"accession_number":"0001437749-26-023538","item_number":"7.01","item_title":"Regulation FD Disclosure","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed announced clinical, plasma biomarker, and imaging data for neflamapimod presented at the Alzheimer's Association International Conference 2026. The disclosure details Phase 2b trial results, PK-PD analyses, and a Phase 2 study of an alternative dose, supporting the company's planned Phase 3 trial design and dose selection. This is a material clinical development milestone for a clinical-stage biotech company's lead drug candidate, but does not fit the specific categories of earnings release, M\u0026A, litigation, or other named event types—it is a material operational/clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:22:43.148257+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-14"},{"id":16501,"accession_number":"0001437749-26-023538","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"CervoMed disclosed new clinical trial data and analyses for neflamapimod presented at AAIC 2026, including Phase 2b RewinD-LB trial results, pharmacokinetic-pharmacodynamic relationships, and Phase 2 study findings for an 80 mg BID dose. The disclosure centers on clinical development progress, dosing strategy refinement, and biomarker/imaging data supporting advancement toward Phase 3 trials—a material operational and strategic milestone for a clinical-stage biopharmaceutical company, though not fitting the specific categories of earnings, M\u0026A, litigation, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:22:43.148257+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-07-14"}]}